Business Context and Reporting Period
This Form 8-K was filed by Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) on August 1, 2022. The filing primarily announces a corporate name change and provides preliminary liquidity data as of June 30, 2022.
Key Financial Metrics
- Liquidity: Approximately $105 million in cash, cash equivalents, and short-term investments as of June 30, 2022.
- Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
- Debt: The filing text does not provide specific values for outstanding debt.
Material Changes
- Corporate Name Change: Effective August 1, 2022, the company changed its name from "Cortexyme, Inc." to "Quince Therapeutics, Inc."
- Trading Symbol: Common stock now trades on the Nasdaq Global Select Market under the new ticker symbol "QNCX," replacing the former "CRTX."
- Governance: The company filed a Certificate of Amendment to its Certificate of Incorporation and amended its bylaws to reflect the name change.
Guidance, Outlook, and Risks
Management issued a press release detailing a "Strategic Growth Plan" in connection with the rebranding. The liquidity figure of $105 million is explicitly stated as a preliminary estimate based on currently available information. The filing notes that this data does not present all necessary information for a complete understanding of the company's financial condition or future operational results. No specific forward-looking financial guidance or quantitative risk factors were detailed in this specific report.
Investor Verification Checklist
- Verify the new ticker symbol "QNCX" on trading platforms.
- Confirm the $105 million liquidity figure in the upcoming audited quarterly report (10-Q) for the period ended June 30, 2022.
- Review the attached press release (Exhibit 99.1) for details on the strategic growth plan.
- Monitor future filings for full financial statements to assess revenue, burn rate, and debt obligations.